Abstract |
The efficacy and patient acceptance of i.m. cefamandole 1 000 mg 8 h and 500 mg 8 h, were compared in the treatment of assumed community-acquired pneumonia in 59 hospitalized adult patients. Of 31 patients treated with 1 000 mg 8 h, 94% had a satisfactory clinical response with a 13% bacteriological failure rate. Of 28 patients treated with 500 mg 8 h, 89% had a satisfactory clinical response with a 60% bacteriological failure rate. The only side effect registered was pain at the injection site after doses of more than 1 000 mg. The pain could be eliminated by the addition of 0.5 ml of lidocaine to the drug solution before injection.
|
Authors | K Mattson, O V Renkonen, A Kohvakka, H Likitalo |
Journal | Scandinavian journal of infectious diseases. Supplementum
(Scand J Infect Dis Suppl)
Vol. suppl 25
Pg. 103-6
( 1980)
ISSN: 0300-8878 [Print] England |
PMID | 7010534
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Cephalosporins
- Cefamandole
|
Topics |
- Adult
- Aged
- Bronchopneumonia
(drug therapy)
- Cefamandole
(therapeutic use)
- Cephalosporins
(therapeutic use)
- Clinical Trials as Topic
- Female
- Haemophilus influenzae
(isolation & purification)
- Humans
- Male
- Middle Aged
- Pleuropneumonia
(drug therapy)
- Pneumonia
(drug therapy)
- Pneumonia, Pneumococcal
(drug therapy)
- Proteus mirabilis
(isolation & purification)
- Streptococcus pneumoniae
(isolation & purification)
|